Author

Michelle Kuzma

Observed names: M. Kuzma, Michelle L. Kuzma

Observed institutions: University of Alberta, University of Pittsburgh, Princess Margaret Cancer Centre, University of Oxford, Cross Cancer Institute

OpenAlex ID: A5065628639

An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity

2010 · Carla M. M. Prado, Isac S. F. Lima, et al. · Cancer Chemotherapy and Pharmacology · 165

Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity

2013 · Vijaya L. Damaraju, Tara Scriver, et al. · Clinical Cancer Research · 42

Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes

2018 · Vijaya L. Damaraju, Michelle Kuzma, et al. · Biochemical Pharmacology · 28

Transepithelial fluxes of adenosine and 2′-deoxyadenosine across human renal proximal tubule cells: roles of nucleoside transporters hENT1, hENT2, and hCNT3

2009 · Adam N. Elwi, Vijaya L. Damaraju, et al. · American Journal of Physiology-Renal Physiology · 27

Characterization of an Anti-MUC1 Monoclonal Antibody with Potential as a Cancer Vaccine

2001 · Weimin Qi, Birgit C. Schultes, et al. · Hybridoma and Hybridomics · 25

Interactions of Multitargeted Kinase Inhibitors and Nucleoside Drugs: Achilles Heel of Combination Therapy?

2014 · Vijaya L. Damaraju, Michelle Kuzma, et al. · Molecular Cancer Therapeutics · 23

Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors

2016 · Vijaya L. Damaraju, Dwayne Weber, et al. · Journal of Biological Chemistry · 21

A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer

2015 · Michael B. Sawyer, Edith Pituskin, et al. · Clinical Breast Cancer · 21

Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures

2008 · Adam N. Elwi, Vijaya L. Damaraju, et al. · Cancer Chemotherapy and Pharmacology · 15

Tyrosine Kinase Inhibitors Reduce Glucose Uptake by Binding to an Exofacial Site on hGLUT‐1: Influence on 18F‐FDG PET Uptake

2020 · Vijaya L. Damaraju, Maral Aminpour, et al. · Clinical and Translational Science · 11

PDF

Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers

2013 · Vijaya L. Damaraju, Delores Mowles, et al. · Biochemistry and Cell Biology · 10

Cytotoxic activities of nucleoside and nucleobase analog drugs in malignant mesothelioma: Characterization of a novel nucleobase transport activity

2008 · Deepti Damaraju, Vijaya L. Damaraju, et al. · Biochemical Pharmacology · 8

Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors

2015 · Vijaya L. Damaraju, Michelle Kuzma, et al. · Cancer Chemotherapy and Pharmacology · 4

Uridine glucuronosyltransferase 2B7 pharmacogenetics predicts epirubicin clearance and myelosuppression

2009 · M. B. Sawyer, S. Damaraju, et al. · Journal of Clinical Oncology · 4

Development of a new equation to estimate creatinine clearance in cancer patients

2015 · Michael P. Chu, Larissa McCaw, et al. · Cancer Chemotherapy and Pharmacology · 3

Abstract 5452: Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors

2015 · Vijaya L. Damaraju, Michelle Kuzma, et al. · Cancer Research

Abstract 797: Interaction of multitargeted tyrosine kinase inhibitors with human nucleoside transporters

2014 · Vijaya L. Damaraju, Michelle Kuzma, et al. · Cancer Research

Development of a new equation to estimate GFR in cancer patients.

2013 · Michael Patvin Chu, Larissa McCaw, et al. · Journal of Clinical Oncology

173 Synergistic toxicity of tyrosine kinase inhibitors with Hsp90 inhibitor 17-AAG in lung cancer cell line

2010 · V.L. Damaraju, M. Wilson, et al. · European Journal of Cancer Supplements

A prospective pharmacogenetic study of thymidylate synthase (TS) polymorphisms in high risk stage II or stage III colon cancer patients treated with 5-fluorouracil (5-FU) and leucovorin (LV)

2006 · K. E. Mulder, C. A. Butts, et al. · Journal of Clinical Oncology

Works count: 20

Citation count: 407

H-index: 10

I10-index: 11